Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
27 09 2021
Historique:
received: 03 02 2020
pubmed: 6 11 2020
medline: 26 11 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

Research indicates that cachexia is common among persons with chronic illnesses and is associated with increased morbidity and mortality. However, there continues to be an absence of a uniformed disease-specific definition for cachexia in chronic kidney disease (CKD) patient populations. The primary objective was to identify cachexia in patients receiving haemodialysis (HD) using a generic definition and then follow up on these patients for 12 months. This was a longitudinal study of adult chronic HD patients attending two hospital HD units in the UK. Multiple measures relevant to cachexia, including body mass index (BMI), muscle mass [mid-upper arm muscle circumference (MUAMC)], handgrip strength (HGS), fatigue [Functional Assessment of Chronic Illness Therapy (FACIT)], appetite [Functional Assessment of Anorexia/Cachexia Therapy (FAACT)] and biomarkers [C-reactive protein (CRP), serum albumin, haemoglobin and erythropoietin resistance index (ERI)] were recorded. Baseline analysis included group differences analysed using an independent t-test, dichotomized values using the χ2 test and prevalence were reported using the Statistical Package for the Social Sciences 24 (IBM, Armonk, NY, USA). Longitudinal analysis was conducted using repeated measures analysis. A total of 106 patients (30 females and 76 males) were recruited with a mean age of 67.6 years [standard deviation (SD) 13.18] and dialysis vintage of 4.92 years (SD 6.12). At baseline, 17 patients were identified as cachectic, having had reported weight loss (e.g. >5% for >6 months) or BMI <20 kg/m2 and three or more clinical characteristics of cachexia. Seventy patients were available for analysis at 12 months (11 cachectic versus 59 not cachectic). FAACT and urea reduction ratio statistically distinguished cachectic patients (P = 0.001). However, measures of weight, BMI, MUAMC, HGS, CRP, ERI and FACIT tended to worsen in cachectic patients. Globally, cachexia is a severe but frequently underrecognized problem. This is the first study to apply the defined characteristics of cachexia to a representative sample of patients receiving HD. Further, more extensive studies are required to establish a phenotype of cachexia in advanced CKD.

Sections du résumé

BACKGROUND
Research indicates that cachexia is common among persons with chronic illnesses and is associated with increased morbidity and mortality. However, there continues to be an absence of a uniformed disease-specific definition for cachexia in chronic kidney disease (CKD) patient populations.
OBJECTIVE
The primary objective was to identify cachexia in patients receiving haemodialysis (HD) using a generic definition and then follow up on these patients for 12 months.
METHOD
This was a longitudinal study of adult chronic HD patients attending two hospital HD units in the UK. Multiple measures relevant to cachexia, including body mass index (BMI), muscle mass [mid-upper arm muscle circumference (MUAMC)], handgrip strength (HGS), fatigue [Functional Assessment of Chronic Illness Therapy (FACIT)], appetite [Functional Assessment of Anorexia/Cachexia Therapy (FAACT)] and biomarkers [C-reactive protein (CRP), serum albumin, haemoglobin and erythropoietin resistance index (ERI)] were recorded. Baseline analysis included group differences analysed using an independent t-test, dichotomized values using the χ2 test and prevalence were reported using the Statistical Package for the Social Sciences 24 (IBM, Armonk, NY, USA). Longitudinal analysis was conducted using repeated measures analysis.
RESULTS
A total of 106 patients (30 females and 76 males) were recruited with a mean age of 67.6 years [standard deviation (SD) 13.18] and dialysis vintage of 4.92 years (SD 6.12). At baseline, 17 patients were identified as cachectic, having had reported weight loss (e.g. >5% for >6 months) or BMI <20 kg/m2 and three or more clinical characteristics of cachexia. Seventy patients were available for analysis at 12 months (11 cachectic versus 59 not cachectic). FAACT and urea reduction ratio statistically distinguished cachectic patients (P = 0.001). However, measures of weight, BMI, MUAMC, HGS, CRP, ERI and FACIT tended to worsen in cachectic patients.
CONCLUSION
Globally, cachexia is a severe but frequently underrecognized problem. This is the first study to apply the defined characteristics of cachexia to a representative sample of patients receiving HD. Further, more extensive studies are required to establish a phenotype of cachexia in advanced CKD.

Identifiants

pubmed: 33150449
pii: 5956377
doi: 10.1093/ndt/gfaa174
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1919-1926

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Clare McKeaveney (C)

School of Nursing and Midwifery, Medical Biology Centre, Queen's University Belfast, Belfast, UK.

Adrian Slee (A)

Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.

Gary Adamson (G)

School of Psychology, Ulster University, Coleraine Campus, Londonderry, UK.

Andrew Davenport (A)

UCL Centre for Nephrology, Royal Free Hospital, University College London, London, UK.

Ken Farrington (K)

Renal Unit, Lister Hospital, East and North Hertfordshire University NHS Trust, Stevenage, UK.

Denis Fouque (D)

Department of Nephrology, Centre Hospitalier Lyon Sud, University Lyon, CARMEN, Pierre-Benite, France.

Kamyar Kalantar-Zadeh (K)

Division of Nephrology and Hypertension, University of California Irvine, Orange, California 92868, USA.

John Mallett (J)

School of Psychology, Ulster University, Coleraine Campus, Londonderry, UK.

Alexander P Maxwell (AP)

Centre for Public Health, Queen's University Belfast, Institute of Clinical Science, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland.
Regional Nephrology Unit, Belfast City Hospital, Belfast Health Social Care Trust, Belfast, BT9 7AB, Northern Ireland.

Robert Mullan (R)

Department of Nephrology, Antrim Area Hospital, Northern Health Social Care Trust, Antrim, BT41 2RL, Northern Ireland.

Helen Noble (H)

School of Nursing and Midwifery, Medical Biology Centre, Queen's University Belfast, Belfast, UK.

Donal O'Donoghue (D)

School of Medicine, University of Manchester, Manchester, UK.

Sam Porter (S)

Department of Social Sciences and Social Work, Bournemouth University, UK.

David S Seres (DS)

Department of Medicine, Columbia University Medical Centre / New York Presbyterian Hospital, New York, USA.

Joanne Shields (J)

Regional Nephrology Unit, Belfast City Hospital, Belfast Health Social Care Trust, Belfast, BT9 7AB, Northern Ireland.

Miles Witham (M)

NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.

Joanne Reid (J)

School of Nursing and Midwifery, Medical Biology Centre, Queen's University Belfast, Belfast, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH